Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

The global Phase III DEEp SEA trial of investigational bexicaserin has completed randomization in children and adults with Dravet syndrome. The milestone advances the broader Phase III DEEp development program evaluating the drug's efficacy, safety and tolerability, but no clinical efficacy data or regulatory timeline was disclosed.